Belatacept（Cat No.:I043486）is a biologic drug used primarily to prevent organ rejection in kidney transplant patients. It is a selective T-cell co-stimulation blocker that inhibits the interaction between CD28 on T-cells and CD80/86 on antigen-presenting cells. This prevents the activation of T-cells, which are responsible for initiating immune responses that can lead to organ rejection. By selectively modulating immune responses, Belatacept helps to reduce the risk of transplant rejection while minimizing the need for long-term immunosuppressive therapies. It offers an alternative to traditional immunosuppressive treatments with potentially fewer side effects.